Literature DB >> 26192168

Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy.

Shoji Kubo1.   

Abstract

The outcome of treatment for hepatitis C virus-related hepatocellular carcinoma is still unsatisfactory because of the high rate of recurrence of cancer, including intrahepatic metastasis and multicentric carcinogenesis after treatment. The rate of recurrence, especially that of multicentric carcinogenesis, is affected by persistent active hepatitis and hepatic fibrosis caused by chronic hepatitis C. Interferon therapy improves the outcome after treatment of hepatocellular carcinoma by decreasing recurrence and preserving or improving liver function when treatment is successful. Radical treatment by anatomic resection and interferon therapy can markedly improve the outcome in patients with hepatitis C virus-related hepatocellular carcinoma.

Entities:  

Keywords:  Hepatitis C virus; Hepatocellular carcinoma; Interferon; Liver resection

Year:  2009        PMID： 26192168     DOI： 10.1007/s12328-009-0072-1

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN： 1865-7265


  57 in total

1.  Patterns of and risk factors for recurrence after liver resection for well-differentiated hepatocellular carcinoma: a special reference to multicentric carcinogenesis after operation.

Authors:  S Kubo; H Kinoshita; K Hirohashi; H Tanaka; T Tsukamoto; H Hamba; T Shuto; T Yamamoto; T Ikebe; K Wakasa
Journal:  Hepatogastroenterology       Date:  1999 Nov-Dec

2.  Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Takahiro Uenishi; Shuhei Nishiguchi; Akihiro Tamori; Takatsugu Yamamoto; Taichi Shuto; Kazuhiro Hirohashi; Shigekazu Takemura; Hiromu Tanaka; Shoji Kubo
Journal:  Hepatol Res       Date:  2006-08-24       Impact factor: 4.288

3.  Risk factors for recurrence after resection of hepatitis C virus-related hepatocellular carcinoma.

Authors:  S Kubo; K Hirohashi; H Tanaka; T Tsukamoto; T Shuto; T Ikebe; T Yamamoto; K Wakasa; S Nishiguchi; T Kuroki; H Kinoshita
Journal:  World J Surg       Date:  2000-12       Impact factor: 3.352

4.  Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group.

Authors: 
Journal:  Lancet       Date:  1998-05-23       Impact factor: 79.321

5.  Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus.

Authors:  Yasushi Shiratori; Shuichiro Shiina; Takuma Teratani; Masatoshi Imamura; Shun'taro Obi; Shin'pei Sato; Yukihiro Koike; Haruhiko Yoshida; Masao Omata
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

6.  Significant influence of accompanying chronic hepatitis status on recurrence of hepatocellular carcinoma after hepatectomy. Result of multivariate analysis.

Authors:  S Ko; Y Nakajima; H Kanehiro; M Hisanaga; Y Aomatsu; T Kin; K Yagura; T Ohyama; K Nishio; K Ohashi; M Sho; T Yamada; H Nakano
Journal:  Ann Surg       Date:  1996-11       Impact factor: 12.969

7.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

8.  Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma.

Authors:  Soocheol Jeong; Hiroshi Aikata; Yoshio Katamura; Takahiro Azakami; Tomokazu Kawaoka; Hiromi Saneto; Kiminori Uka; Nami Mori; Shintaro Takaki; Hideaki Kodama; Koji Waki; Michio Imamura; Hiroo Shirakawa; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

9.  Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

Authors:  Y Imai; S Kawata; S Tamura; I Yabuuchi; S Noda; M Inada; Y Maeda; Y Shirai; T Fukuzaki; I Kaji; H Ishikawa; Y Matsuda; M Nishikawa; K Seki; Y Matsuzawa
Journal:  Ann Intern Med       Date:  1998-07-15       Impact factor: 25.391

10.  Relationship between multicentric occurrence of hepatocellular carcinoma and histology of noncancerous hepatic tissue in patients with chronic hepatitis C.

Authors:  S Kubo; T Yamamoto; T Ikebe; T Shuto; K Hirohashi; H Tanaka; T Tsukamoto; K Wakasa; H Kinoshita
Journal:  Jpn J Cancer Res       Date:  1999-10
View more
  1 in total

Review 1.  Adjuvant therapy after curative resection for hepatocellular carcinoma associated with hepatitis virus.

Authors:  Shoji Kubo; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Takahiro Uenishi
Journal:  Liver Cancer       Date:  2013-01       Impact factor: 11.740
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.